- Previous Close
2.5500 - Open
2.6300 - Bid 2.4700 x --
- Ask 2.6300 x --
- Day's Range
2.6100 - 2.6500 - 52 Week Range
2.0800 - 8.4000 - Volume
2,961 - Avg. Volume
992 - Market Cap (intraday)
15.861M - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
3.14 - EPS (TTM)
0.8300 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
www.biofrontera.com88
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: B8FK.DE
View More
Performance Overview: B8FK.DE
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: B8FK.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: B8FK.DE
View MoreValuation Measures
Market Cap
15.86M
Enterprise Value
13.25M
Trailing P/E
3.16
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.87
Price/Book (mrq)
0.94
Enterprise Value/Revenue
0.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-20.08%
Return on Assets (ttm)
-12.30%
Return on Equity (ttm)
-22.40%
Revenue (ttm)
21.67M
Net Income Avi to Common (ttm)
-4.35M
Diluted EPS (ttm)
0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.12M
Total Debt/Equity (mrq)
4.06%
Levered Free Cash Flow (ttm)
-1.15M